Tirzepatide treatment and achieving weight reduction >5%, SBP reduction >5 mmHg and non-HDL cholesterol reduction >10%: A post hoc analysis from the SURMOUNT-1 3-year trial
29 August 2025 (07:00 - 18:00)
Organised by: 
About the speaker
University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)
6 More presentations in this session
Associate Professor L. Bikdelu (Mashhad, IR)
Doctor D. Sa (Funchal, PT)
Doctor D. Corsi (New Brunswick, US)
Doctor G. Bettencourt Abreu (Funchal, PT)
Access the full session
The Event
ESC Congress 2025
29 August - 1 September 2025
You may be interested in
Congress Presentation
Congress Presentation
